AMVAX-B 1ML Vaccine at Chughtai Lab

AMVAX-B 1ML Vaccine at Chughtai Lab

The AMVAX-B 1ML Vaccine at Chughtai Lab is a premier immunization service designed to provide robust, long-term active immunity against the Hepatitis B virus (HBV). Hepatitis B is a highly infectious and potentially life-threatening viral pathogen that targets the liver, leading to acute illness, chronic liver disease, cirrhosis, and hepatocellular carcinoma (liver cancer). The AMVAX-B vaccine is a non-infectious, sterile recombinant DNA vaccine. It contains purified hepatitis B surface antigen (HBsAg), which is produced using advanced genetic engineering technology. Specifically, the gene coding for HBsAg is inserted into the yeast Saccharomyces cerevisiae, which then synthesizes the antigen. This antigen is meticulously purified and adsorbed onto an aluminum hydroxide adjuvant to enhance the body’s immune response, ensuring maximum immunogenicity and protective efficacy without any risk of causing the actual disease.

When administered at Chughtai Lab, the AMVAX-B 1ML Vaccine works by introducing this harmless antigen to the patient’s immune system. The antigen-presenting cells (APCs) process the HBsAg and present it to T-helper cells, which in turn activate B-lymphocytes. These B-cells proliferate and differentiate into plasma cells that produce highly specific neutralizing antibodies known as anti-HBs. Additionally, the vaccine induces the formation of immunological memory cells (both memory B and T-cells). If the vaccinated individual is exposed to the actual Hepatitis B virus in the future, these memory cells recognize the pathogen instantly, triggering a rapid and massive production of anti-HBs antibodies to neutralize the virus before it can infect hepatic cells. This clinical mechanism provides a highly effective shield, with clinical studies demonstrating a seroprotection rate of over 95% to 99% in healthy individuals who complete the recommended vaccination course.

The clinical importance of the AMVAX-B 1ML Vaccine cannot be overstated. Hepatitis B is transmitted through exposure to infective blood, semen, and other body fluids. It can be contracted via needle-stick injuries, unsafe injection practices, blood transfusions, sexual contact, and vertically from an infected mother to her newborn during childbirth. Because chronic Hepatitis B is often asymptomatic for decades, many individuals remain unaware of their infection until they present with end-stage liver disease. Therefore, active immunization is the most reliable, cost-effective, and medically sound strategy to eliminate the risk of transmission. Chughtai Lab, Pakistan’s leading diagnostic network, offers this vaccine under strict clinical supervision, ensuring that patients receive authentic, properly stored, and professionally administered vaccines to safeguard their long-term hepatic health.

Clinical Procedure: What to Expect

Patient Preparation

• No Fasting Required: Unlike routine blood tests, there is absolutely no requirement to fast before receiving the AMVAX-B 1ML Vaccine. You may eat and drink normally.
• Medical History Disclosure: Inform the healthcare professional at Chughtai Lab if you have a history of severe allergic reactions (anaphylaxis) to yeast or any previous dose of a Hepatitis B vaccine.
• Current Health Status: If you are experiencing an acute moderate-to-severe illness accompanied by a high fever, it is clinically advisable to postpone the vaccination until you recover. Mild infections, such as a common cold without fever, are not contraindications.
• Medication Review: Disclose all current medications, especially immunosuppressive therapies, chemotherapy, or systemic corticosteroids, as these may reduce the vaccine’s immunological efficacy. Also, inform the staff if you are on anticoagulant therapy (blood thinners) to minimize post-injection bruising.
• Appropriate Attire: Wear loose-fitting clothing or a short-sleeved shirt that allows easy and comfortable access to the upper arm, specifically the deltoid muscle.
• Vaccination Records: Bring any prior immunization cards or records to help the clinician document the dose correctly and schedule your subsequent booster doses accurately.

During the Procedure

• Patient Positioning: You will be asked to sit comfortably in a designated vaccination chair. Relaxing the arm muscle is essential to minimize discomfort during the injection.
• Aseptic Preparation: The Chughtai Lab medical professional will sanitize their hands, put on sterile gloves, and clean the injection site (typically the deltoid muscle of your non-dominant arm) using a 70% isopropyl alcohol swab in a circular outward motion.
• Vaccine Inspection: The clinician will visually inspect the AMVAX-B 1ML vial or pre-filled syringe for any particulate matter, discoloration, or damage, ensuring the vaccine is at room temperature and thoroughly homogenized.
• Administration Technique: Using a sterile, single-use syringe with an appropriate needle gauge (typically 22 to 25 gauge), the clinician will perform an intramuscular (IM) injection. The needle is inserted at a 90-degree angle directly into the thickest part of the deltoid muscle.
• Duration: The actual injection process is extremely brief, lasting only about 5 to 10 seconds.
• Post-Injection Care: A sterile cotton swab will be pressed gently against the injection site for a few seconds to control any minor bleeding, followed by the application of an adhesive bandage.
• Safety Observation: You will be requested to remain in the waiting area at Chughtai Lab for 15 to 30 minutes post-administration. This standard safety protocol allows medical staff to monitor you for any rare, immediate systemic allergic reactions or vasovagal episodes (fainting).

When is a AMVAX-B 1ML Vaccine Performed?

Active Immunization Against Hepatitis B Virus

The primary clinical indication for administering the AMVAX-B 1ML Vaccine is to establish active, long-term immunity against the Hepatitis B virus. Physicians routinely recommend this vaccine for all unvaccinated individuals, including infants, children, adolescents, and adults. Because Hepatitis B is highly contagious and can survive on environmental surfaces for up to seven days, universal vaccination is the cornerstone of public health. By administering the complete three-dose series, the body develops a robust immunological defense, effectively preventing the development of both acute and chronic HBV infections, thereby reducing the global burden of chronic liver disease.

Occupational Safety for Healthcare Professionals

Healthcare workers, including doctors, nurses, laboratory technologists, dentists, and clinical students, are at an exceptionally high risk of occupational exposure to Hepatitis B. This exposure typically occurs through accidental needle-stick injuries, cuts from sharp surgical instruments, or direct contact of infectious blood and body fluids with mucous membranes or non-intact skin. Physicians and occupational health departments mandate the AMVAX-B 1ML Vaccine for all clinical personnel. Ensuring a protective antibody titer among healthcare staff not only protects the workers themselves but also prevents nosocomial (hospital-acquired) transmission to vulnerable patients.

Pre-Travel Immunization for Endemic Regions

Travelers planning to visit geographic regions with high or intermediate prevalence rates of Hepatitis B (such as parts of Sub-Saharan Africa, East Asia, the Amazon basin, and the Middle East) are strongly advised to receive the AMVAX-B vaccine. The risk of exposure increases significantly if travelers require medical or dental care, receive tattoos or piercings, or engage in close personal contact during their stay. Physicians request the vaccine series well in advance of travel to ensure that the patient has developed protective anti-HBs antibody levels before entering high-risk environments.

Management of High-Risk Clinical Cohorts

Certain patient populations are highly susceptible to acquiring Hepatitis B or developing severe, life-threatening complications if infected. These high-risk cohorts include patients with chronic kidney disease (especially those undergoing long-term hemodialysis), individuals with chronic liver diseases (such as Hepatitis C or non-alcoholic fatty liver disease), patients with diabetes mellitus, individuals with HIV infection, and those receiving immunosuppressive therapies. Physicians proactively prescribe the AMVAX-B 1ML Vaccine to these patients to prevent opportunistic infections and avoid the devastating consequences of viral superinfections on compromised physiological systems.

Post-Exposure Prophylaxis (PEP) Protocols

In cases of known or suspected exposure to the Hepatitis B virus, rapid intervention is critical to prevent the establishment of infection. Common exposure scenarios include accidental needle-stick injuries involving blood from an HBsAg-positive source, sexual assault, or infants born to HBsAg-positive mothers. In these emergency situations, physicians initiate a post-exposure prophylaxis protocol that includes the immediate administration of the AMVAX-B 1ML Vaccine alongside Hepatitis B Immune Globulin (HBIG). This combination provides immediate passive immunity (via HBIG) while simultaneously stimulating the patient’s own immune system to develop active, long-term protection.

What Does a AMVAX-B 1ML Vaccine Detect?

While the AMVAX-B 1ML Vaccine is an immunizing agent rather than a diagnostic test, its administration is closely linked to specific immunological parameters, physiological responses, and clinical safety findings. The clinical evaluation of a patient undergoing AMVAX-B vaccination involves monitoring the following key outcomes, protective indicators, and safety markers:

• Seroconversion Status: The primary immunological finding, defined as the development of protective anti-HBs antibodies following vaccination.
• Anti-HBs Antibody Titer: A quantitative laboratory measurement where a titer of ≥ 10 mIU/mL indicates successful, protective immunity.
• Hyper-Responder Status: An exceptionally strong immune response characterized by anti-HBs antibody titers exceeding 100 mIU/mL or even 1000 mIU/mL.
• Hypo-Responder Status: A weak immune response where antibody titers remain between 1 and 9 mIU/mL after a complete primary series, requiring booster doses.
• Non-Responder Status: The absence of protective antibodies (titer < 1 mIU/mL) after vaccination, often seen in elderly, obese, or immunocompromised individuals.
• Active Humoral Immunity: The successful stimulation of B-lymphocytes to produce neutralizing immunoglobulin G (IgG) antibodies against HBsAg.
• Immunological Memory Activation: The establishment of long-lived memory B and T-cells that persist even when circulating antibody levels decline over time.
• Prevention of Acute Hepatitis B: Clinical protection against acute hepatic inflammation, characterized by the absence of jaundice, dark urine, and elevated liver enzymes.
• Prevention of Chronic HBV Carrier State: The elimination of the risk of becoming a chronic carrier of the virus, thereby preventing ongoing transmission.
• Prevention of Liver Cirrhosis: Long-term protection against the progressive scarring and destruction of healthy liver parenchyma caused by chronic HBV.
• Prevention of Hepatocellular Carcinoma: A significant reduction in the lifetime risk of developing primary liver cancer, making AMVAX-B one of the first anti-cancer vaccines.
• Prevention of Hepatitis D Co-infection: Because the Hepatitis D virus requires the outer envelope of HBV to replicate, AMVAX-B effectively prevents Delta virus infection.
• Normal Local Tissue Response: Mild, transient erythema (redness) at the injection site, indicating a healthy localized inflammatory response to the antigen.
• Normal Local Physiological Response: Mild induration (hardness) or swelling at the injection site that typically resolves spontaneously within 48 hours.
• Transient Localized Tenderness: Mild soreness in the deltoid muscle, which is a common and expected physiological reaction to intramuscular antigen deposition.
• Absence of Systemic Hypersensitivity: The confirmation that the patient does not experience immediate allergic reactions, such as generalized urticaria or angioedema.
• Absence of Immediate Anaphylaxis: The critical safety finding of no severe, life-threatening allergic reactions during the post-injection observation period.
• Normal Post-Vaccine Body Temperature: The absence of high-grade fever, though a mild, self-limiting low-grade pyrexia may occasionally occur as the immune system activates.
• Absence of Vaccine-Induced Vasculitis: The monitoring and confirmation of no rare systemic autoimmune or inflammatory vascular complications post-administration.
• Preservation of Normal Hepatic Enzymes: Maintaining normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, confirming no active hepatic injury.
• Prevention of Vertical Transmission: Successful protection of newborns from perinatal transmission when administered immediately after birth to HBsAg-positive mothers.
• Prevention of Horizontal Transmission: Protection of household contacts and sexual partners of known Hepatitis B carriers through active immunization.
• Completion of Primary Immunization Schedule: Documenting the successful administration of all three doses (typically at 0, 1, and 6 months) for maximum efficacy.
• Long-Term Immunological Persistence: The continuous presence of protective immune memory, often lasting for 20 years or more without the need for routine boosters.
• Safe Administration in Special Populations: Confirming the safety and tolerability of the vaccine in pregnant women, lactating mothers, and elderly patients when clinically indicated.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the administration of the AMVAX-B 1ML Vaccine is documented immediately. Upon receiving the injection, patients are provided with an official, physical Chughtai Lab Vaccination Card. This card is a crucial medical document that records the exact brand name (AMVAX-B), the specific manufacturer batch and lot number, the date of administration, the dosage administered (1ML), and the signature of the clinical professional who performed the procedure. Most importantly, the card clearly outlines the scheduled dates for your subsequent doses to ensure you complete the full immunization series without delay.

In addition to the physical card, Chughtai Lab leverages its advanced digital infrastructure to update your immunization records in real-time. Patients can access their digital vaccination history through the secure Chughtai Lab Patient Portal or the user-friendly Chughtai Lab Mobile App. If a patient undergoes a post-vaccination Anti-HBs antibody blood test to verify their immunity level, the laboratory report for this test is typically processed and made available online within 12 to 24 hours of sample collection, providing rapid and convenient access to your clinical data.

AMVAX-B 1ML Vaccine Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-HBs Antibody Titer	≥ 10 mIU/mL (Indicates protective immunity against Hepatitis B)	< 10 mIU/mL (Indicates non-protective levels or non-responder status)
Injection Site Reaction	Mild, transient redness, swelling, or localized soreness resolving within 48 hours	Severe pain, persistent swelling, sterile abscess, or localized cellulitis (infection)
Systemic Temperature	Apyrexial (Normal body temperature) or mild, self-limiting low-grade fever (< 38°C)	High-grade fever (> 38.5°C) or prolonged pyrexia requiring medical evaluation
Immediate Allergic Response	No signs of allergic reaction; skin and respiratory functions remain entirely normal	Anaphylaxis, bronchospasm, generalized urticaria, or angioedema (requires emergency care)
Liver Function Tests (Post-Exposure)	Normal ALT, AST, and Bilirubin levels, indicating healthy hepatic function	Elevated transaminases, indicating acute hepatic injury or active Hepatitis B infection
HBsAg Status	Negative (The vaccine does not cause a positive HBsAg test result)	Positive (Indicates active acute or chronic Hepatitis B infection, unrelated to the vaccine)
Immunological Memory	Robust activation of memory B and T-lymphocytes for long-term protection	Impaired memory response, commonly associated with advanced immunosuppression
Muscle Tissue Integrity	No long-term damage or persistent nodule formation at the injection site	Deep muscle hematoma (especially in patients with unmanaged bleeding disorders)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for AMVAX-B 1ML Vaccine?

• Strict Cold Chain Maintenance: Chughtai Lab adheres to stringent international standards for cold chain management, ensuring that the AMVAX-B vaccine is continuously stored and transported at optimal temperatures (2°C to 8°C) to preserve its potency and efficacy.
• Qualified Healthcare Professionals: Every vaccine is administered by highly trained, certified nursing staff and medical professionals who follow rigorous aseptic techniques and patient safety protocols.
• Home Vaccination Services: For patients who prefer the comfort and convenience of their homes, Chughtai Lab offers professional home vaccination services, bringing clinical excellence directly to your doorstep.
• Digital Immunization Records: Your vaccination history is securely stored in Chughtai Lab’s digital database, allowing you to access and download your official immunization certificate anytime via the mobile app or online portal.
• State-of-the-Art Facilities: Chughtai Lab’s extensive network of clinics and collection centers across Pakistan features modern, clean, and comfortable environments designed to provide a stress-free patient experience.
• Comprehensive Pre-Vaccination Screening: Prior to administration, our clinical staff conduct a brief, thorough screening to assess your health status, review contraindications, and answer any clinical questions you may have.
• Robust Emergency Protocols: All Chughtai Lab vaccination centers are fully equipped with emergency medical kits, including epinephrine, to manage rare, immediate allergic reactions safely and effectively.
• Widespread Network Accessibility: With hundreds of locations across major cities like Lahore, Karachi, and Islamabad, completing your multi-dose AMVAX-B vaccine schedule on time is highly convenient.